Our data indicate that the frequency of TNFR2 expression on PB CD4+ T cells could become a novel and easily accessible marker, which can be used to predict clinical outcomes or monitor the progress of AML patients subjected to standard cytotoxic therapy. This evidence concerns the gene CD4 and acute myeloid leukemia.